Overview
Cumberland Q2 2025 revenue rises 10% yr/yr to $10.8 mln
Year-to-date revenue up 23% over first half of 2024
Co announces Vibativ 4-Vial Starter Pak availability through Vizient
Outlook
Company expresses optimism for continued success in clinical programs
Cumberland optimistic about building on first-half success
Result Drivers
PRODUCT PORTFOLIO - FDA-approved brands contributed to a 10% revenue increase in Q2 2025
VIBATIV AVAILABILITY - New supply arrangement with Vizient enhances Vibativ treatment flexibility
CLINICAL PROGRESS - Phase II FIGHT DMD trial shows promising results for ifetroban in improving cardiac function
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | $10.80 mln | ||
Q2 Operating Expenses | $11.60 mln |
Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Press Release: ID:nPn3qxwh8a
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。